Literature DB >> 20816677

Predictive value of serum apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk: population-based cohort study.

Altan Onat1, Günay Can, Gökhan Ciçek, Erkan Ayhan, Yüksel Doğan.   

Abstract

OBJECTIVES: We determined the independent predictive value of serum apolipoprotein (apo) B/LDL-cholesterol ratio for the risk of diabetes, metabolic syndrome (MetS) and coronary heart disease (CHD). DESIGN AND METHODS: Prediction of incident cases was assessed in 2466 adults at 7 years' follow-up.
RESULTS: ApoB/LDL ratio was independently associated log-linearly with waist circumference, and, only in men, with HDL-cholesterol in a multivariable regression model. Positive partial correlations existed with fasting insulin, fibrinogen and apo A-I and, only in women, with CRP. Cox regression analyses revealed the two highest apoB/LDL quartiles to be significant determinants of diabetes, at 2-fold RRs, independently of waist circumference, fasting glucose and other confounders. However, apoB/LDL quartiles were not independently associated with CHD in either gender. Only the highest apoB/LDL quartile was associated (RR 1.46) with the development of MetS. Serum apoB/LDL-cholesterol ratio, determined by insulin resistance and in women additionally by pro-inflammatory state, is of independent predictive value for incident diabetes and weakly for MetS, but not for CHD.
Copyright © 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816677     DOI: 10.1016/j.clinbiochem.2010.08.027

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  7 in total

1.  Minor allele of the APOA4 gene T347S polymorphism predisposes to obesity in postmenopausal Turkish women.

Authors:  Filiz Guclu-Geyik; Altan Onat; Neslihan Coban; Evrim Komurcu-Bayrak; Vedat Sansoy; Günay Can; Nihan Erginel-Unaltuna
Journal:  Mol Biol Rep       Date:  2012-10-25       Impact factor: 2.316

Review 2.  Novel treatment strategies for brain tumors and metastases.

Authors:  Salma E El-Habashy; Alaa M Nazief; Chris E Adkins; Ming Ming Wen; Amal H El-Kamel; Ahmed M Hamdan; Amira S Hanafy; Tori O Terrell; Afroz S Mohammad; Paul R Lockman; Mohamed Ismail Nounou
Journal:  Pharm Pat Anal       Date:  2014-05

3.  Oxidized HDL and LDL in adolescents with type 2 diabetes compared to normal weight and obese peers.

Authors:  Monica T Marin; Paul S Dasari; Jeanie B Tryggestad; Christopher E Aston; April M Teague; Kevin R Short
Journal:  J Diabetes Complications       Date:  2015-04-06       Impact factor: 3.219

4.  Associations of apolipoprotein B/apolipoprotein A-I ratio with pre-diabetes and diabetes risks: a cross-sectional study in Chinese adults.

Authors:  Shuang Zheng; Tingting Han; Hua Xu; Huan Zhou; Xingxing Ren; Peihong Wu; Jun Zheng; Lihua Wang; Ming Zhang; Yihong Jiang; Yawen Chen; Huiying Qiu; Wei Liu; Yaomin Hu
Journal:  BMJ Open       Date:  2017-01-20       Impact factor: 2.692

5.  The association between the apolipoprotein A1/ high density lipoprotein -cholesterol and diabetes in Taiwan - a cross-sectional study.

Authors:  Zhi-Hong Jian; Chia-Chi Lung; Pei-Chieh Ko; Yi-Hua Sun; Jing-Yang Huang; Chien-Chang Ho; Chia-Yo Ho; Yi-Chen Chiang; Chien-Jen Chen; Yung-Po Liaw
Journal:  BMC Endocr Disord       Date:  2013-10-07       Impact factor: 2.763

6.  Longitudinal associations of high-density lipoprotein cholesterol or low-density lipoprotein cholesterol with metabolic syndrome in the Chinese population: a prospective cohort study.

Authors:  Xiao-Rong Wang; Gui-Rong Song; Meng Li; Hong-Ge Sun; Yong-Jun Fan; Ying Liu; Qi-Gui Liu
Journal:  BMJ Open       Date:  2018-05-09       Impact factor: 2.692

7.  Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.

Authors:  Shigemasa Tani; Tsukasa Yagi; Wataru Atsumi; Kenji Kawauchi; Rei Matsuo; Atsushi Hirayama
Journal:  Cardiovasc Diabetol       Date:  2017-10-02       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.